Detail

Professor Lichtenberg teaches the core course Global Economic Environment. His research examines how the introduction of new technology arising from research and development affects the productivity of companies, industries and nations. Recently, he has studied the impact of new drugs on hospitalization rates, the effect of computers on productivity in business and government organizations and the consequences of takeovers and LBOs for efficiency and employment. A research associate of the National Bureau of Economic Research, Lichtenberg has received numerous research fellowships and grants, served as a consultant to a variety of private and public organizations and testified before Congress.

• Winner of the 1998 Schumpeter Prize
  For the paper "Pharmaceutical innovation as a process of creative destruction"
• 2003 Milken Institute Award for Distinguished Economic Research
  For the paper "Pharmaceutical knowledge-capital accumulation and longevity"

• Fall 2009
  Global Economic Environment I & II
  
Managerial Economics

• Spring 2009
  Economics of Health Care & Pharmaceuticals
  
Economics of Healthcare & Pharmaceuticals

• Fall 2008
  Global Economic Environment
  
Managerial Economics

• Spring 2008
  Economics of Healthcare & Pharmaceuticals
  
• Fall 2007
  Global Economic Environment
  
The Global Economic Environment

• Fall 2006
  Economics of Health Care & Pharmaceuticals
  

Pharmaceutical Knowledge-Capital Accumulation and Longevity In Measuring Capital in the New Economy (2005) Coauthor(s): Frank Lichtenberg

Availability of New Drugs and Americans' Ability to Work In Journal of Occupational and Environmental Medicine (2005) Coauthor(s): Frank Lichtenberg

The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982-2001 In International Journal of Health Care Finance and Economics (2005) Coauthor(s): Frank Lichtenberg

The Effects of Medicare on Health Care Utilization and Outcomes In Frontiers in Health Policy Research (2002) Coauthor(s): Frank Lichtenberg

Do (More and Better) Drugs Keep People Out of Hospitals? In American Economic Review (1996) Coauthor(s): Frank Lichtenberg

The Private R and D Investment Response to Federal Design and Technical Competitions In American Economic Review (1988) Coauthor(s): Frank Lichtenberg

The Comparative Advantage of Educated Workers in Implementing New Technology In Review of Economics and Statistics (1987) Coauthor(s): Ann Bartel, Frank Lichtenberg

Corporate Takeovers and Productivity In (1992) Coauthor(s): Frank Lichtenberg

The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth In NBER Working Papers, Working Paper 15068 (2009) Coauthor(s): Frank Lichtenberg

Benefits and Costs of Newer Drugs: An Update In Working paper (2005) Coauthor(s): Frank Lichtenberg

Pharmaceutical-Embodied Technical Progress, Longevity, and Quality of Life: Drugs as 'Equipment for Your Health' In Working paper (2005) Coauthor(s): Frank Lichtenberg, Suchin Virabhak

Sources of U.S. Longevity Increase, 1960-1997 In Working paper (2005) Coauthor(s): Frank Lichtenberg

The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry In Working paper (2005) Coauthor(s): Frank Lichtenberg

The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output In Working paper (2005) Coauthor(s): Frank Lichtenberg

The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs? In Working paper (2005) Coauthor(s): Adriana Lleras-Muney, Frank Lichtenberg

The Expanding Pharmaceutical Arsenal in the War on Cancer In NBR Working Paper 10328 (2005) Coauthor(s): Frank Lichtenberg

The Impact of New Drug Launches on Longevity: From 52 Countries, 1982-2001 In Working paper (2005) Coauthor(s): Frank Lichtenberg

The Effect of New Drugs on Mortality from Rare Diseases and HIV In NBER Working Paper 8677 (2002) Coauthor(s): Frank Lichtenberg

The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey In NBER Working Paper 8147 (2001) Coauthor(s): Frank Lichtenberg

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth In NBER Working Paper W6569 (1998) Coauthor(s): Frank Lichtenberg

The Allocation of Publicly-Funded Biomedical Research In NBER Working Paper 6601 (1998) Coauthor(s): Frank Lichtenberg

The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality In NBER Working Paper No. W5418 (1996) Coauthor(s): Frank Lichtenberg